Loading...
Market
Highest revenue growth rate for ATTR-CM companies in 2025?
2
Resolution / Starting Odds
BridgeBio Pharma • 25%
Pfizer • 25%
Other • 25%
Tie • 25%
Company financial reports and industry analysis
Story
FDA Approves BridgeBio's Attruby (Acoramidis), First Near-Complete TTR Stabilizer for ATTR-CM
Nov 23, 2024, 12:14 AM
BridgeBio Pharma (ticker symbol $BBIO) announced that the U.S. Food and Drug Administration (FDA) has approved Attruby™ (acoramidis), an orally administered near-complete transthyretin (TTR) stabilizer for the treatment of adult patients with transthyretin cardiac amyloidosis (ATTR-CM). Attruby, the first and only approved product specifying near-complete stabilization of TTR (≥90%), was designed to mimic a naturally occurring 'rescue mutation' of the TTR gene (T119M), targeting the root cause of ATTR-CM by preventing destabilization of the native TTR tetramer. The drug is approved to reduce cardiovascular death and cardiovascular-related hospitalization in ATTR-CM patients. The approval sets up competition with Pfizer, which also markets a treatment for ATTR-CM. Attruby will be priced at approximately $245,000 per year.
View original story
Similar markets
Less than 10% • 25%
10% to 20% • 25%
20% to 30% • 25%
More than 30% • 25%
Yes • 50%
No • 50%
Less than 10% • 25%
10%-20% • 25%
20%-30% • 25%
More than 30% • 25%
Pfizer • 25%
Ionis Pharmaceuticals • 25%
Eidos Therapeutics • 25%
Other • 25%
Travere Therapeutics • 25%
Novartis • 25%
Calliditas • 25%
Other • 25%
Purdue Pharma • 25%
ARS Pharmaceuticals • 25%
Pfizer • 25%
Other • 25%
Apple • 25%
Microsoft • 25%
Nvidia • 25%
Other • 25%
Less than 5% • 25%
5% to 10% • 25%
10% to 15% • 25%
More than 15% • 25%
Nvidia • 25%
Apple • 25%
Microsoft • 25%
Tie • 25%
Ascendis Pharma • 25%
Takeda • 25%
Another existing company • 25%
A new entrant • 25%
Afami-cel • 25%
Cosibelimab • 25%
Adagrasib-Cetuximab • 25%
Other • 25%